Nicolino Tufilli

Title: Nicolino Tufilli: Innovator in EGFR Inhibitors

Introduction

Nicolino Tufilli is a notable inventor based in Möhlin, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors for specific biological targets.

Latest Patents

Tufilli holds a patent for polymorphic forms of (S)—N-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine. This compound is recognized for its potential as an EGFR inhibitor, which is crucial in the treatment of various cancers. The patent outlines methods of preparation and the use of this compound in therapeutic applications.

Career Highlights

Nicolino Tufilli is associated with Katmai Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work focuses on innovative solutions in the pharmaceutical industry, contributing to the creation of effective treatments.

Collaborations

Tufilli has collaborated with notable colleagues such as Jean-Michel Vernier and Fritz Blatter. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Nicolino Tufilli's contributions to the field of pharmaceuticals, particularly through his patent on EGFR inhibitors, highlight his role as an innovator. His work continues to impact the development of effective treatments in the medical field.